Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: BMT CTN 1102

• Published in: American journal of hematology Vol. 98; no. 2; pp. 229 - 250
• Main Authors: Cusatis, Rachel, Martens, Michael J., Nakamura, Ryotaro, Cutler, Corey S., Saber, Wael, Lee, Stephanie J., Logan, Brent R., Shaw, Bronwen E., Gregory, Alyssa, D'Souza, Anita, Hamilton, Betty K., Horowitz, Mary M., Flynn, Kathryn E.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.02.2023; Wiley Subscription Services, Inc
• Subjects: Aged; Clinical trials; Hematology; Hematopoietic Stem Cell Transplantation - methods; Humans; Myelodysplastic syndrome; Myelodysplastic syndromes; Myelodysplastic Syndromes - therapy; Patients; Quality of Life; Stem cell transplantation; Tissue Donors; Transplantation; Transplantation Conditioning - methods; Transplants & implants

For myelodysplastic syndrome (MDS), allogeneic hematopoietic cell transplantation (alloHCT) is the only available curative therapy. The Blood and Marrow Transplant Clinical Trials Network study 1102 (BMT CTN 1102, NCT02016781) was a multicenter, biologic assignment trial based on matched donor avail...